Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies

Zhenlong Ye, Yongmei Ding, Zhuo Chen, Zhong Li, Shuo Ma, Zenghui Xu, Liang Cheng, Xinyue Wang, Xiaoxia Zhang, Na Ding, Qian Zhang, Qijun Qian

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was 89.0% in diagnosed cancer patients (ranging from 75.0% to 100.0%). Average number of 11, 5, 8 and 4 CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer, respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8, polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM expression was more frequently found in most CTCs than vimentin expression, confirming that these CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to predict and evaluate therapeutic efficacy as well as to monitoring disease progression.

Original languageEnglish (US)
Pages (from-to)546-551
Number of pages6
JournalCancer Biology and Therapy
Volume20
Issue number4
DOIs
StatePublished - Apr 3 2019

Fingerprint

Circulating Neoplastic Cells
Aneuploidy
Neoplasms
Chromosomes, Human, Pair 8
Polyploidy
Tetraploidy
Vimentin
Liver Neoplasms
Fluorescence In Situ Hybridization
Carcinoma
Kidney Neoplasms
Ploidies

Keywords

  • Circulating tumor cells
  • CTCs
  • EpCAM
  • iFISH
  • Vimentin

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. / Ye, Zhenlong; Ding, Yongmei; Chen, Zhuo; Li, Zhong; Ma, Shuo; Xu, Zenghui; Cheng, Liang; Wang, Xinyue; Zhang, Xiaoxia; Ding, Na; Zhang, Qian; Qian, Qijun.

In: Cancer Biology and Therapy, Vol. 20, No. 4, 03.04.2019, p. 546-551.

Research output: Contribution to journalArticle

Ye, Z, Ding, Y, Chen, Z, Li, Z, Ma, S, Xu, Z, Cheng, L, Wang, X, Zhang, X, Ding, N, Zhang, Q & Qian, Q 2019, 'Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies', Cancer Biology and Therapy, vol. 20, no. 4, pp. 546-551. https://doi.org/10.1080/15384047.2018.1538000
Ye, Zhenlong ; Ding, Yongmei ; Chen, Zhuo ; Li, Zhong ; Ma, Shuo ; Xu, Zenghui ; Cheng, Liang ; Wang, Xinyue ; Zhang, Xiaoxia ; Ding, Na ; Zhang, Qian ; Qian, Qijun. / Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. In: Cancer Biology and Therapy. 2019 ; Vol. 20, No. 4. pp. 546-551.
@article{639a9d2a148643119982734ccc0649fe,
title = "Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies",
abstract = "Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was 89.0{\%} in diagnosed cancer patients (ranging from 75.0{\%} to 100.0{\%}). Average number of 11, 5, 8 and 4 CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer, respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8, polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM expression was more frequently found in most CTCs than vimentin expression, confirming that these CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to predict and evaluate therapeutic efficacy as well as to monitoring disease progression.",
keywords = "Circulating tumor cells, CTCs, EpCAM, iFISH, Vimentin",
author = "Zhenlong Ye and Yongmei Ding and Zhuo Chen and Zhong Li and Shuo Ma and Zenghui Xu and Liang Cheng and Xinyue Wang and Xiaoxia Zhang and Na Ding and Qian Zhang and Qijun Qian",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/15384047.2018.1538000",
language = "English (US)",
volume = "20",
pages = "546--551",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies

AU - Ye, Zhenlong

AU - Ding, Yongmei

AU - Chen, Zhuo

AU - Li, Zhong

AU - Ma, Shuo

AU - Xu, Zenghui

AU - Cheng, Liang

AU - Wang, Xinyue

AU - Zhang, Xiaoxia

AU - Ding, Na

AU - Zhang, Qian

AU - Qian, Qijun

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was 89.0% in diagnosed cancer patients (ranging from 75.0% to 100.0%). Average number of 11, 5, 8 and 4 CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer, respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8, polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM expression was more frequently found in most CTCs than vimentin expression, confirming that these CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to predict and evaluate therapeutic efficacy as well as to monitoring disease progression.

AB - Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was 89.0% in diagnosed cancer patients (ranging from 75.0% to 100.0%). Average number of 11, 5, 8 and 4 CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer, respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8, polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM expression was more frequently found in most CTCs than vimentin expression, confirming that these CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to predict and evaluate therapeutic efficacy as well as to monitoring disease progression.

KW - Circulating tumor cells

KW - CTCs

KW - EpCAM

KW - iFISH

KW - Vimentin

UR - http://www.scopus.com/inward/record.url?scp=85059030446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059030446&partnerID=8YFLogxK

U2 - 10.1080/15384047.2018.1538000

DO - 10.1080/15384047.2018.1538000

M3 - Article

VL - 20

SP - 546

EP - 551

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 4

ER -